How Pathogen-Derived Cysteine Proteases Modulate Host Immune Responses

  • Sheila Donnelly
  • John P. Dalton
  • Mark W. Robinson
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 712)


In mammals, cysteine proteases are essential for the induction and development of both innate and adaptive immune responses. These proteases play a role in antigen-and pathogen-recognition and elimination, signal processing and cell homeostasis. Many pathogens also secrete cysteine proteases that often act on the same target proteins as the mammalian proteases and thereby can modulate host immunity from initial recognition to effector mechanisms. Pathogen-derived proteases range from nonspecific proteases that degrade multiple proteins involved in the immune response to enzymes that are very specific in their mode of action. Here, we overview current knowledge of pathogen-derived cysteine proteases that modulate immune responses by altering the normal function of key receptors or pathways in the mammalian immune system.


Periodontal Disease Severe Acute Respiratory Syndrome Severe Acute Respiratory Syndrome Porphyromonas Gingivalis Entamoeba Histolytica 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Colbert JD, Matthews SP, Miller G et al. Diverse regulatory roles for lysosomal proteases in the immune response. Eur J Immunol 2009; 39:2955–2965.PubMedGoogle Scholar
  2. 2.
    Bird PI, Trapani JA, Villadangos JA. Endolysosomal proteases and their inhibitors in immunity. Nat Rev Immunol 2009; 9:871–882.PubMedGoogle Scholar
  3. 3.
    Robinson MW, Menon R, Donnelly SM et al. An integrated transcriptomics and proteomics analysis of the secretome of the helminth pathogen Fasciola hepatica: proteins associated with invasion and infection of the mammalian host. Mol Cell Proteomics 2009; 8:1891–1907.PubMedGoogle Scholar
  4. 4.
    Robinson MW, Dalton JP, Donnelly S. Helminth pathogen cathepsin proteases: it’s a family affair. Trends Biochem Sci 2008; 33:601–608.PubMedGoogle Scholar
  5. 5.
    McKerrow JH, Caffrey C, Kelly B et al. Proteases in parasitic diseases. Annu Rev Pathol 2006; 1:497–536.PubMedGoogle Scholar
  6. 6.
    Imamura T. The role of gingipains in the pathogenesis of periodontal disease. J Periodontol 2003;74:111–118.PubMedGoogle Scholar
  7. 7.
    Onoe T, Hoover CI, Nakayama K et al. Identification of Porphyromonas gingivalis prefimbrilin possessing a long leader peptide: possible involvement of trypsin-like protease in fimbrilin maturation. Microb Pathog 1995; 19:351–364.PubMedGoogle Scholar
  8. 8.
    Maliar T, Baláz S, Tandlich R et al. Viral proteinases—possible targets of antiviral drugs. Acta Virol 2002; 46:131–140.PubMedGoogle Scholar
  9. 9.
    Harcourt BH, Jukneliene D, Kanjanahaluethai A et al. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. Virol 2004; 78:13600–13612.Google Scholar
  10. 10.
    Edelmann MJ, Kessler BM. Ubiquitin and ubiquitin-like specific proteases targeted by Infectious pathogens: Emerging patterns and molecular principles. Biochim Biophys Acta 2008; 1782:809–816.PubMedGoogle Scholar
  11. 11.
    Alexander J, Bryson K. T helper (h) 1/th2 and Leishmania: paradox rather than paradigm. Immunol Lett 2005; 99:17–23.PubMedGoogle Scholar
  12. 12.
    Maekawa Y, himeno K, Katunuma N. Cathepsin B-inhibitor promotes the development of Th1 type protective T-cells in mice infected with Leishmania major. J Med Invest 1997; 44:33–39.PubMedGoogle Scholar
  13. 13.
    Maekawa Y, Himeno K, Ishikawa H et al. Switch of CD4+ T-cell differentiation from Th2 to Th1 by treatment with cathepsin B inhibitor in experimental leishmaniasis. J Immunol 1998; 161:2120–2127.PubMedGoogle Scholar
  14. 14.
    Denise H, McNeil K, Brooks DR et al. Expression of multiple CPB genes encoding cysteine proteases is required for Leishmania mexicana virulence in vivo. Infect Immun 2003;71:3190–3195.PubMedGoogle Scholar
  15. 15.
    Pollock KG, McNeil KS, Mottram JC et al. The Leishmania mexicana cysteine protease, CPB2.8, induces potent Th2 responses. J Immunol 2003; 170:1746–1753.PubMedGoogle Scholar
  16. 16.
    Giordanengo L, Guiñazú N, Stempin C et al. Cruzipain, a major Trypanosoma cruzi antigen, conditions the host immune response in favor of parasite. Eur J Immunol 2002; 32:1003–1011.PubMedGoogle Scholar
  17. 17.
    Sokol CL, Barton GM, Farr AG et al. A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat Immunol 2008; 9:310–318.PubMedGoogle Scholar
  18. 18.
    Sokol CL, Chu NQ, Yu S et al. Basophils function as antigen-presenting cells for an allergen-induced T helper type 2 response. Nat Immunol 2009; 10:713–720.PubMedGoogle Scholar
  19. 19.
    Phillips C, Coward WR, Pritchard DI et al. Basophils express a type 2 cytokine profile on exposure to proteases from helminths and house dust mites. J Leukoc Biol 2003; 73:165–171.PubMedGoogle Scholar
  20. 20.
    Brady MT, O’Neill SM, Dalton JP et al. Fasciola hepatica suppresses a protective Th1 response against Bordetella pertussis. Infect Immun 1999; 67:5372–5378.PubMedGoogle Scholar
  21. 21.
    O’Neill SM, Brady MT, Callanan JJ et al. Fasciola hepatica infection downregulates Th1 responses in mice. Parasite Immunol 2000; 22:147–155.PubMedGoogle Scholar
  22. 22.
    O’Neill SM, Mills KH, Dalton JP. Fasciola hepatica cathepsin L cysteine proteinase suppresses Bordetella pertussis-specific interferon-gamma production in vivo. Parasite Immunol 2001; 23:541–547.PubMedGoogle Scholar
  23. 23.
    Pearce EJ, MacDonald AS. The immunobiology of schistosomiasis. Nat Rev Immunol. 2002; 2:499–511.PubMedGoogle Scholar
  24. 24.
    Sung CK, Dresden MH. Cysteinyl proteinases of Schistosoma mansoni eggs: purification and partial characterization. J Parasitol. 1986; 72: 891–900.PubMedGoogle Scholar
  25. 25.
    Donnelly S, O’Neill SM, Stack CM et al. Helminth cysteine proteases inhibit TRIF-dependent activation of macrophages via degradation of TLR3. J Biol Chem. 2010; 285:3383–3392.PubMedGoogle Scholar
  26. 26.
    Dowling DJ, Hamilton CM, Donnelly S et al. Major secretory antigens of the helminth Fasciola hepatica activate a suppressive dendritic cell phenotype that attenuates Th17 cells but fails to activate th2 immune responses. Infect Immun 2010; 78:793–801.PubMedGoogle Scholar
  27. 27.
    Potempa J, Pike RN. Corruption of innate immunity by bacterial proteases. J Innate Immun 2009; 1:70–87.PubMedGoogle Scholar
  28. 28.
    Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783–801.PubMedGoogle Scholar
  29. 29.
    Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11:373–384.PubMedGoogle Scholar
  30. 30.
    Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 4:499–511.Google Scholar
  31. 31.
    O’Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7:353–364.PubMedGoogle Scholar
  32. 32.
    Kawai T, Akira S. Signaling to NF-KappaB by Toll-like receptors. Trends Mol Med 2007; 13:460–469.PubMedGoogle Scholar
  33. 33.
    Slots J, Ting M. Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in human periodontal disease: occurrence and treatment. Periodontol 1999; 20:82–121.Google Scholar
  34. 34.
    Holt SC, Kesavalu L, Walker S et al. Virulence factors of Porphyromonas gingivalis. Periodontol 1999; 20:168–238.Google Scholar
  35. 35.
    Gioannini TL, Weiss JP. Regulation of interactions of Gram-negative bacterial endotoxins with mammalian cells. Immunol Res 2007; 39:249–260.PubMedGoogle Scholar
  36. 36.
    Sugawara S, Nemoto E, Tada H et al. Proteolysis of human monocyte CD14 by cysteine proteinases (gingipains) from Porphyromonas gingivalis leading to lipopolysaccharide hyporesponsiveness J Immunol 2000; 165:411–418.PubMedGoogle Scholar
  37. 37.
    Duncan L, Yoshioka M, Chandad F et al. Loss of lipopolysaccharide receptor CD14 from the surface of human macrophage-like cells mediated by Porphyromonas gingivalis outer membrane vesicles. Microb Pathog 2004; 36:319–325.PubMedGoogle Scholar
  38. 38.
    Kim JI, Lee CJ, Jin MS et al. Crystal structure of CD14 and its implications for lipopolysaccharide signaling. J Biol Chem 2005; 280:11347–11351.PubMedGoogle Scholar
  39. 39.
    Tada H, Sugawara S, Nemoto E et al. Proteolysis of CD14 on human gingival fibroblasts by arginine-specific cysteine proteinases from Porphyromonas gingivalis leading to down-regulation of lipopolysaccharide-induced interleukin-8 production. Infect Immun 2002; 70:3304–3307.PubMedGoogle Scholar
  40. 40.
    Imamura T. The role of gingipains in the pathogenesis of periodontal disease. J Periodontol. 2003; 74:111–118.PubMedGoogle Scholar
  41. 41.
    Lowther J, Robinson MW, Donnelly SM et al. The importance of pH in regulating the function of the Fasciola hepatica cathepsin L1 cysteine protease. PloS Negl Trop Dis 2009; 3:e369.PubMedGoogle Scholar
  42. 42.
    Stack CM, Donnelly S, Lowther J et al. The major secreted cathepsin L1 protease of the liver fluke, Fasciola hepatica: a Leu-12 to Pro-12 replacement in the nonconserved C-terminal region of the prosegment prevents complete enzyme autoactivation and allows definition of the molecular events in prosegment removal. J Biol Chem 2007; 282:16532–16543.PubMedGoogle Scholar
  43. 43.
    Ferrero E, Hsieh CL, Francke U et al. CD14 is a member of the family of leucine-rich proteins and is encoded by a gene syntenic with multiple receptor genes. J Immunol 1990; 145:331–336.PubMedGoogle Scholar
  44. 44.
    Ranjith-Kumar CT, Miller W, Xiong J et al. Biochemical and Functional Analyses of the Human Toll-like Receptor 3 Ectodomain. J Biol Chem 2007; 282:7668–7678.PubMedGoogle Scholar
  45. 45.
    Kanaji S, Tanaka Y, Sakata Y et al. Squamous cell carcinoma antigen 1 is an inhibitor of parasite-derived cysteine proteases. FEBS Lett 2007; 581:4260–4264.PubMedGoogle Scholar
  46. 46.
    Kopitar-Jerala N. The role of cystatins in cells of the immune system. FEBS Lett 2006; 580:295–301.Google Scholar
  47. 47.
    Kane CM, Cervi L, Sun J et al. Helminth antigens modulate TLR-initiated dendritic cell activation. J Immunol 2004; 173:7454–7461.PubMedGoogle Scholar
  48. 48.
    van Liempt E, van Vliet SJ, Engering A et al. Schistosoma mansoni soluble egg antigens are internalized by human dendritic cells through multiple C-type lectins and suppress TLR-induced dendritic Cell activation. Mol Immunol 2007; 44:2605–2615.PubMedGoogle Scholar
  49. 49.
    Alexander J, Satoskar AR, Russell DG. Leishmania species: models of intracellular parasitism. J Cell Sci 1999; 112:2993–2998.PubMedGoogle Scholar
  50. 50.
    Reiner SL, Zheng S, Wang AE et al. Leishmania promastigotes evade interleukin-12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T-cells during initiation of infection. J Exp Med 1994; 179:447–252.PubMedGoogle Scholar
  51. 51.
    Carrera L, Gazzinelli RT, Badolato R et al. Leishmania promastigotes selectively inhibit interleukin-12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J Exp Med 1996; 183:515–520.PubMedGoogle Scholar
  52. 52.
    Heinzel FP, Schoenhaut DS, Rerko RM et al. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993; 177:1505–1510.PubMedGoogle Scholar
  53. 53.
    Sypek JP, Chung CL, Mayor SHE et al. Resolution of cutaneous leishmaniasis: interleukin-12 initiates a protective T helper type 1 immune response. J Exp Med 1993; 177:1797–1802.PubMedGoogle Scholar
  54. 54.
    Afonso LCC, Scharton TM, Vieira, LQ et al. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994; 263:235–240.PubMedGoogle Scholar
  55. 55.
    Buxbaum LU, Hubert D, Coombs GH et al. CPB cysteine proteases of Leishmania mexicana inhibit host Th1 responses and protective immunity. J Immunol 2003; 171:3711–3718.PubMedGoogle Scholar
  56. 56.
    Cameron P, McGachy A, Anderson M et al. Inhibition of lipopolysaccharide-induced macrophage IL-12 production by Leishmania mexicana amastigotes: the role of cysteine peptidases and the NF-kappaB signaling pathway. J Immunol 2004; 173:3297–3304.PubMedGoogle Scholar
  57. 57.
    Shapira S, Harb OS, Margarit J et al. Initiation and termination of NF-kappaB signaling by the intracellular protozoan parasite Toxoplasma gondii. J Cell Sci 2005; 118:3501–3508.PubMedGoogle Scholar
  58. 58.
    Roiko MS, Carruthers VB. New roles for perforins and proteases in apicomplexan egress. Cell Microbiol 2009; 11:1444–1452.PubMedGoogle Scholar
  59. 59.
    Nijman SM, Luna-Vargas MP, Velds A. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005; 123:773–786.PubMedGoogle Scholar
  60. 60.
    Levy DE, Garcia-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev 2001; 12:143–156.PubMedGoogle Scholar
  61. 61.
    Barretto N, Jukneliene D, Ratia K et al. The Papain like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity, J Virol 2005; 79:15189–15198.PubMedGoogle Scholar
  62. 62.
    Ratia K, Pegan S, Takayama J et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl acad Sci USA 2008; 105:16119–16124.PubMedGoogle Scholar
  63. 63.
    Frieman M, Ratia K, Johnston RE et al. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol 2009; 83:6689–6705.PubMedGoogle Scholar
  64. 64.
    Frieman M, Heise M, Baric R. SARS coronavirus and innate immunity. Virus Res 2007; 133:101–112.PubMedGoogle Scholar
  65. 65.
    Zhou H, Perlman S. Mouse hepatitis virus does not induce Beta interferon synthesis and does not inhibit its induction by doublestranded RNA. J Virol 2007; 81:568–574.PubMedGoogle Scholar
  66. 66.
    Versteeg GA, Bredenbeek PJ, van den Worm SH et al. Group 2 coronaviruses prevent immediate early interferon induction by protection of viral RNA from host Cell recognition. Virology 2007; 361:18–26.PubMedGoogle Scholar
  67. 67.
    Hengel H, Koszinowski UH, Conzelmann KK. Viruses know it all: new insights into IFN networks. Trends Immunol 2005; 26:396–401.PubMedGoogle Scholar
  68. 68.
    Kattenhorn LM, Korbel GA, Kessler BM et al. A deubiquitinating enzyme encoded by HSV-1 belongs to a family of cysteine proteases that is conserved across the family herpesviridae. Mol. Cell 2005; 19:547–557.PubMedGoogle Scholar
  69. 69.
    Schlieker C, Korbel GA, Kattenhorn LM et al. A deubiquitinating activity is conserved in the large tegument protein of the Herpesviridae. J Virol 2005; 79:15582–15585.PubMedGoogle Scholar
  70. 70.
    Wang J, Loveland AN, Kattenhorn LM et al. High-molecular-weight protein (pUL48) of human cytomegalovirus is a competent deubiquitinating protease: mutant viruses altered in its activesite cysteine or histidine are viable. J Virol 2006; 80:6003–6012.PubMedGoogle Scholar
  71. 71.
    Balakirev MY, Jaquinod M, Haas AL et al. Deubiquitinating function of adenovirus proteinase. J Virol 2002; 76:6323–6331.PubMedGoogle Scholar
  72. 72.
    Barretto N, Jukneliene D, Ratia K et al. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J Virol 2005; 79:15189–15198.PubMedGoogle Scholar
  73. 73.
    Sweet CR, Conlon J, Golenbock DT et al. Yop J targets TRAF proteins to inhibit TLR-mediated NF-kappaB, MAPK and IRF3 signal transduction. Cell Microbiol 2007; 9:2700–2715.PubMedGoogle Scholar
  74. 74.
    Zhou H, Monack DM, Kayagaki N et al. Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-kappa B activation. J Exp Med 2005; 202:1327–1332.PubMedGoogle Scholar
  75. 75.
    Orth K, Xu Z, Mudgett MB et al. Disruption of signaling by Yersinia effector YopJ, a ubiquitin-like protein protease. Science 2000; 290:1594–1597.PubMedGoogle Scholar
  76. 76.
    Ye Z, Petrof EO, Boone D et al. Salmonella effector AvrA regulation of colonic epithelial cell inflammation by deubiquitination, Am J Pathol 2007; 171:882–892.PubMedGoogle Scholar
  77. 77.
    Misaghi S, Balsara ZR, Catic A et al. Chlamydia trachomatis-derived deubiquitinating enzymes in mammalian cells during infection. Mol Microbiol 2006; 61:142–150.PubMedGoogle Scholar
  78. 78.
    Catic A, Misaghi A, Korbel GA et al. ElaD, a deubiquitinating protease expressed by E. coli. PloS ONE 2007; 2:e381.PubMedGoogle Scholar
  79. 79.
    Ponder EL, Bogyo M. Ubiquitin-like modifiers and their deconjugating enzymes in medically important parasitic protozo A, Eukaryot. Cell 2007; 6:1943–1952.Google Scholar
  80. 80.
    Artavanis-Tsakonas K, Misaghi S, Comeaux CA et al. Identification by functional proteomics of a deubiquitinating/deNeddylating enzyme in Plasmodium falciparum. Mol Microbiol 2006; 61:1187–1195.PubMedGoogle Scholar
  81. 81.
    Frickel EM, Quesada V, Muething L et al. Apicomplexan UCHL3 retains dual specificity for ubiquitin and Nedd8 throughout evolution. Cell Microbiol 2007; 9:1601–1610.PubMedGoogle Scholar
  82. 82.
    Kostura MJ, Tocci MJ, Limjuco G et al. Identification of a monocyte specific pre-interleukin 1 beta convertase activity. Proc Natl acad Sci USA 1989; 86:5227–5231.PubMedGoogle Scholar
  83. 83.
    Black RA, Kronheim SR, Merriam JE et al. A pre-aspartate-specific protease from human leukocytes that cleaves pro-interleukin-1 beta. J Biol Chem 1989; 264:5323–5326.PubMedGoogle Scholar
  84. 84.
    Kapur V, Majesky MW, Li LL et al Cleavage of interleukin 1 beta (IL-1 beta) precursor to produce active IL-1 beta by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc Natl acad Sci USA 1993; 90:7676–7680.PubMedGoogle Scholar
  85. 85.
    Zhang Z, Wang L, Seydel KB et al. Entamoeba histolytica cysteine proteinases with interleukin-1 beta converting enzyme (ICE) activity cause intestinal inflammation and tissue damage in amoebiasis. Mol Microbiol 2000; 37:542–548.PubMedGoogle Scholar
  86. 86.
    Que X, Kim SH, Sajid M et al. A surface amebic cysteine proteinase inactivates interleukin-18. Infect Immun 2003; 71:1274–1280.PubMedGoogle Scholar
  87. 87.
    Kim SH, Azam T, Novick D et al. Identification of amino acid residues critical for biological activity in human interleukin-18. J Biol Chem 2002; 277:10998–11003.PubMedGoogle Scholar
  88. 88.
    Wolf M, Albrecht S, Märki C. Proteolytic processing of chemokines: implications in physiological and pathological conditions. Int J Biochem Cell Biol 2008; 40:1185–1198.PubMedGoogle Scholar
  89. 89.
    Dean RA, Cox JH, Bellac CL et al. Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, 7, 8 and 13 antagonists: potential role of the macrophage in terminating PMN influx. Blood 2008;112:3455–3464.PubMedGoogle Scholar
  90. 90.
    Mikolajczyk-Pawlinska J, Travis J, Potempa J. Modulation of interleukin-8 activity by gingipains from Porphyromonas gingivalis: implications for pathogenicity of periodontal disease. FEBS Lett 1998; 440:282–286.PubMedGoogle Scholar
  91. 91.
    O’Neill SM, Parkinson M, Strauss W et al. Immunodiagnosis of Fasciola hepatica infection (fascioliasis) in a human population in the Bolivian Altiplano using purified cathepsin L cysteine proteinase. Am J Trop Med Hyg 1998; 58:417–423.PubMedGoogle Scholar
  92. 92.
    Duffus WP, Thorne K, Oliver R. Killing of juvenile Fasciola hepatica by purified bovine eosinophil proteins. Clin Exp Immunol 1980; 40:336–344.PubMedGoogle Scholar
  93. 93.
    Duffus WP, Franks D. In vitro effect of immune serum and bovine granulocytes on juvenile Fasciola hepatica. Clin Exp Immunol 1980; 41:430–440.PubMedGoogle Scholar
  94. 94.
    Carmona C, Dowd AJ, Smith AM et al. Ccathepsin L proteinase secreted by Fasciola hepatica in vitro prevents antibody-mediated eosinophil attachment to newly excysted juveniles. Mol Biochem Parasitol 1993; 62:9–17.PubMedGoogle Scholar
  95. 95.
    Berasain P, Carmona C, Frangione B et al. Fasciola hepatica:parasite-secreted proteinases degrade all human IgG subclasses: determination of the specific cleavage sites and identification of the immunoglobulin fragments produced. Exp Parasitol 2000; 94:99–110.PubMedGoogle Scholar
  96. 96.
    Chung YB, Yang HJ, Kang SY et al. Activities of different cysteine proteases of Paragonimus westermani in cleaving human IgG. Korean J Parasitol 1997; 35:139–142.PubMedGoogle Scholar
  97. 97.
    Kong Y, Chung YB, Cho SY et al. Cleavage of immunoglobulin G by excretory-secretory cathepsin S-like protease of Spirometra mansoni plerocercoid. Parasitology 1994;109:611–621.PubMedGoogle Scholar
  98. 98.
    Auriault C, Ouaissi MA, Torpier G et al. Proteolytic cleavage of IgG bound to the Fc receptor of Schistosoma mansoni schistosomula. Parasite Immunol 1981; 3:33–44.PubMedGoogle Scholar
  99. 99.
    Shin MH, Kita H, Park HY et al. Cysteine protease secreted by Paragonimus westermani attenuates effector functions of human eosinophils stimulated with immunoglobulin. G Infect Immun 2001; 69:1599–1604.Google Scholar
  100. 100.
    Berasain P, Carmona C, Frangione B et al. Specific cleavage sites on human IgG subclasses by cruzipain, the major cysteine proteinase from Trypanosoma cruzi. Mol Biochem Parasitol 2003; 130:23–29.PubMedGoogle Scholar
  101. 101.
    Wenig K, Chatwell L, von Pawel-Rammingen U et al. Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG. Proc Natl Acad Sci USA. 2004; 101: 17371–17376.PubMedGoogle Scholar
  102. 102.
    von Pawel-rammingen U, Johansson BP, Björck L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin. G EMBO J 2002; 21:1607–1615.Google Scholar
  103. 103.
    von Pawel-Rammingen U, Björck L. IdeS and SpeB: immunoglobulin-degrading cysteine proteinases of Streptococcus pyogenes. Curr Opin Microbiol 2003; 6:50–55.Google Scholar
  104. 104.
    Collin M, Olsén A. Effect of SpeB and EndoS from Streptococcus pyogenes on human immunoglobulins. Infect Immun 2001; 69:7187–7189.PubMedGoogle Scholar
  105. 105.
    Plaut AG. The Igal proteases of pathogenic bacteria. Annu Rev Microbiol 1983; 37:603–622.PubMedGoogle Scholar
  106. 106.
    Kilian M, Mestecky J, Russell MW. Defense mechanisms involving Fc-dependent functions of immunoglobulin a and their subversion by bacterial immunoglobulin a proteases. Microbiol Rev 1988; 52:296–303.PubMedGoogle Scholar
  107. 107.
    Mistry D, Stockley RA. Iga1 protease. Int J Biochem Cell Biol 2006; 8:1244–1248.Google Scholar
  108. 108.
    Garcia-Nieto RM, RicoMata R, Arias-Negrete S et al. Degradation of human secretory Iga1 and Iga2 by Entamoeba histolytica surface-associated proteolytic activity. Parasitol Int 2008; 57:417–423.PubMedGoogle Scholar
  109. 109.
    Que X, Reed SL. Cysteine proteinases and the pathogenesis of amebiasis. Clin Microbiol Rev 2000; 13:196–206.PubMedGoogle Scholar
  110. 110.
    Kuo CF, Lin YS, Chuang WJ et al. Degradation of complement 3 by streptococcal pyrogenic exotoxin B inhibits complement activation and neutrophil opsonophagocytosis. Infect Immun 2008; 76:1163–1169.PubMedGoogle Scholar
  111. 111.
    Terao Y, Mori Y, Yamaguchi M et al. Group A streptococcal cysteine protease degrades C3 (C3b) and contributes to evasion of innate immunity. J Biol Chem 2008; 283:6253–6260.PubMedGoogle Scholar
  112. 112.
    Reed SL, Ember JA, Herdman DS et al. The extracellular neutral cysteine proteinase of Entamoeba histolytica degrades anaphylatoxins C3a and C5a. J Immunol 1995; 155:266–274.PubMedGoogle Scholar
  113. 113.
    Popadiak K, Potempa J, Riesbeck K et al. Biphasic effect of gingipains from Porphyromonas gingivalis on the human complement system. J Immunol 2007; 178:7242–7250.PubMedGoogle Scholar
  114. 114.
    Potempa M, Potempa J, Kantyka T et al. Interpain A, a cysteine proteinase from Prevotella intermedia, inhibits complement by degrading complement factor C3. PloS Pathog 2009; 5:e1000316.PubMedGoogle Scholar
  115. 115.
    Lathem WW, Bergsbaken T, Welch RA. Potentiation of C1 esterase inhibitor by StcE, a metalloprotease secreted by Escherichia coli O157:H7. J Exp Med 2004; 199:1077–1087.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Sheila Donnelly
    • 1
  • John P. Dalton
    • 2
  • Mark W. Robinson
    • 1
  1. 1.Institute (formerly IBID)University of TechnologySydneyAustralia
  2. 2.Institute of ParasitologyMcGill UniversitySt. Anne de BellevueCanada

Personalised recommendations